Abstract
Current treatment regimens for gastric cancer are not adequate. Cancer stem cells (CSCs) may be a key driving factor for growth and metastasis of this tumor type. In contrast to the conventional clonal evolution hypothesis, CSCs can initiate tumor formation, self-renew, and differentiate into tumor-propagating cells. Because gastric cancer can originate from CSCs, it is necessary to review current targets of signaling pathways for CSCs in gastric cancer that are being studied in clinical trials. These pathways are known to regulate the self-renewal and differentiation process in gastric CSCs. A better understanding of the clinical results of trials that target gastric CSCs will lead to better outcomes for patients with gastric cancer. Cancer 2017;123:1303–1312.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1303-1312 |
| Number of pages | 10 |
| Journal | Cancer |
| Volume | 123 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 15 2017 |
Keywords
- cancer stem cells
- clinical trials
- gastric cancer
- napabucasin
- targeted therapy
- vismodeqib
ASJC Scopus subject areas
- Oncology
- Cancer Research